Dermatology Best Practices 2026: A Clinician’s Guide

The pace of clinical development in dermatology has rarely moved this fast. Between new FDA approvals, AI-assisted diagnostics, and precision laser platforms, dermatology best practices 2026 look meaningfully different from just two years ago. This guide cuts through the noise and gives you a structured, criteria-based look at what is actually worth integrating into your practice today. Whether you focus on medical dermatology, cosmetic procedures, or both, what follows is built for clinicians who need clarity, not a catalog of buzzwords.

Table of Contents

• Key takeaways
• 1. How to evaluate dermatology best practices in 2026
• 2. New FDA-approved therapies shaping treatment in 2026
• 3. Bio-regenerative treatments and the evolving aesthetic paradigm
• 4. Precision laser technologies and skin equity
• 5. AI-assisted diagnostics: what they actually do well
• 6. Comparative analysis of top treatments and technologies
• 7. Integrating best practices into your clinical workflow
• My honest take on where dermatology is headed in 2026
• See how Raodermatology delivers on these standards
• FAQ

Key takeaways

Point	Details
New FDA approvals matter	Delgocitinib cream offers the first approved topical option for adults with moderate-to-severe chronic hand eczema.
Pediatric guidelines have changed	The AAD now explicitly discourages systemic corticosteroids in patients under 18 except as short-term bridge therapy.
AI assists, not replaces	AI diagnostic tools improve workflow efficiency but require paired dermatologist assessment to optimize patient outcomes.
Cosmetic market is expanding fast	The facial injectables market is projected to reach nearly $30 billion by 2036, reshaping practice economics now.
Practice valuation rewards tech adoption	Practices combining AI, teledermatology, and cosmetic growth tend to clear at 8 to 12 times EBITDA multiples.

1. How to evaluate dermatology best practices in 2026

Before adopting any new therapy or technology, you need a clear evaluative framework. The volume of emerging options is high enough that without structured criteria, practices risk adopting tools that look impressive on paper but underdeliver clinically.

The most reliable criteria to apply when assessing any 2026 dermatology practice update include:

• Clinical efficacy: How strong is the evidence base? Look for randomized controlled trials, FDA review data, and head-to-head comparisons with existing treatments.
• Safety across skin types: With growing attention to equity in dermatology, any treatment or device must demonstrate safety and efficacy across Fitzpatrick skin types I through VI.
• Technology integration: Does the tool fit into your existing workflow, or does it require a complete rebuild of patient management systems?
• Patient-centered outcomes: Are improvements physiological, cosmetic, or both? The best practices in 2026 address both categories for a more complete patient experience.
• Economic viability: Consider cost of acquisition, reimbursement landscape, and long-term ROI. Total cost of ownership for advanced technology includes service contracts, consumables, and staff training, which significantly impact ROI beyond the initial purchase price.
• Adaptability to precision medicine: Does the practice or technology support personalized treatment planning based on individual patient biology, lifestyle, and skin characteristics?

Pro Tip: When evaluating a new technology, ask the vendor for outcome data from practices with a similar patient demographic mix. A device that performs well in a predominantly lighter-skin population may need additional calibration protocols for your specific patient base.

2. New FDA-approved therapies shaping treatment in 2026

The most significant regulatory milestone in recent dermatology history came with the FDA approval of delgocitinib cream, first topical treatment for adults with moderate-to-severe chronic hand eczema who have not responded to other therapies. Clinical trial data showed consistent efficacy regardless of prior systemic therapy exposure, which positions it well for patients who have exhausted conventional options.

On the pediatric side, the American Academy of Dermatology released its first-ever guidelines specifically for pediatric atopic dermatitis. These 26 evidence-based recommendations cover topical therapies, phototherapy, and systemic options, and they take a firm stance against systemic corticosteroids in patients under 18 except as short-term bridge therapy. For clinicians who treat pediatric patients, this is not a minor update. It represents a meaningful shift in the standard of care.

Pro Tip: When counseling families about pediatric eczema management, lead with the safety rationale for avoiding long-term corticosteroids before presenting alternatives. Parents are more receptive to newer systemic options when they understand the evidence-based reasoning rather than feeling a familiar treatment is being withheld.

Beyond eczema, the biologics and JAK inhibitor pipeline continues to mature, with several agents showing durable remission in moderate-to-severe psoriasis and atopic dermatitis across broader patient groups. These agents are increasingly the backbone of systemic therapy protocols.

3. Bio-regenerative treatments and the evolving aesthetic paradigm

One of the most significant cosmetic dermatology trends 2026 is the shift toward bio-regenerative approaches. Rather than simply filling or relaxing, the focus is now on stimulating the skin’s own repair mechanisms for sustained improvement. Treatments such as platelet-rich plasma, exosome-based therapies, and next-generation polynucleotide injectables are gaining traction precisely because patients now frame aesthetic care as science-backed self-care rather than purely cosmetic intervention.

This perception shift has real clinical implications. Patients arriving for consultations in 2026 are more informed, more evidence-oriented, and more likely to ask for specific mechanisms of action behind what you recommend. Your ability to explain the biology behind bio-regenerative treatments is now part of clinical credibility.

The facial injectables market is expected to nearly double from $15.64 billion in 2026 to $29.94 billion by 2036, with botulinum toxin holding a 45% market share and a projected CAGR of 6.7%. Understanding where the market is headed helps practices make strategic decisions about which procedures to expand and which tools to invest in now.

4. Precision laser technologies and skin equity

Laser dermatology has historically underserved patients with darker skin types. That gap is narrowing in 2026. Precision laser systems that dynamically adjust energy output based on real-time skin response are now commercially available and represent a major advance in safety and equity across Fitzpatrick types IV through VI.

Combination procedures are also redefining outcomes. Layering technologies such as BBL and HALO lasers produces synergistic treatment results that neither modality achieves alone, addressing multiple skin concerns in fewer sessions. This approach is increasingly the standard for patients seeking rejuvenation rather than isolated correction.

Treatment stacking also improves patient retention. When patients see measurable, multi-dimensional results, they return for maintenance and are more likely to refer others. From both a clinical and a practice-growth standpoint, combination protocols are worth building into your service offerings.

5. AI-assisted diagnostics: what they actually do well

AI tools in dermatology are genuinely useful for a specific set of tasks. They speed diagnosis, reduce referral wait times, and improve access in underserved populations. When integrated into a teledermatology workflow, AI triage tools can flag high-priority lesions and prioritize scheduling without burdening clinical staff.

What they do not do well is replace clinical judgment. The practices that are extracting the most value from AI in 2026 are those using it to handle workflow bottlenecks, not clinical decision-making. Think of AI as a well-trained triage nurse who reads charts efficiently, not as a consultant you hand cases off to without review.

For practices considering AI adoption, explore how technology reshapes dermatology workflows before committing to a specific platform. The best tools are those that reduce administrative friction without creating new dependencies that slow down the patient encounter.

6. Comparative analysis of top treatments and technologies

The following comparison reflects the current state of leading therapeutic and technology categories for 2026 clinical decision-making.

Treatment or technology	Efficacy	Safety for skin of color	Cost and ROI	Best use case
Delgocitinib cream	High (moderate-to-severe CHE)	Not a concern (topical)	Moderate; good reimbursement outlook	Adults with refractory chronic hand eczema
JAK inhibitors (systemic)	High for AD and psoriasis	Generally well tolerated	Higher cost; monitor for REMS requirements	Moderate-to-severe AD or psoriasis
Biologics (IL-17, IL-23 inhibitors)	Very high for psoriasis	Safe; limited skin type data	High acquisition; strong long-term response	Plaque psoriasis with systemic involvement
AI-assisted diagnostics	Moderate (triage accuracy)	Requires diverse training data	Low to moderate; strong workflow ROI	High-volume practices and teledermatology
Precision laser systems	High with proper calibration	Excellent when dynamically adjusted	High acquisition; strong patient retention ROI	Rejuvenation in diverse skin type populations
Bio-regenerative injectables	Growing evidence base	Minimal risk; no thermal injury	Moderate; strong patient demand	Patients prioritizing skin repair over volume

Practice valuations in 2026 increasingly reward technology integration, with practices combining medical stability and cosmetic growth clearing at 8 to 12 times EBITDA multiples. Knowing which tools drive that valuation matters as much as knowing which ones improve clinical outcomes.

7. Integrating best practices into your clinical workflow

Knowing what works is only part of the challenge. Getting it into your workflow without disrupting patient care or overwhelming staff is where most practices struggle. A structured adoption approach makes the difference.

1. Audit your current protocols. Before adding anything new, map your existing workflows for patient intake, diagnosis, treatment planning, and follow-up. Identify where delays or inconsistencies occur.
2. Pilot before scaling. Introduce new therapies or technologies with a defined cohort of patients before rolling out practice-wide. This limits risk and generates internal outcome data you can use for staff training.
3. Train staff alongside technology adoption. The patient engagement platforms that perform best in 2026 are those where the entire care team understands the tool, not just the physician.
4. Address reimbursement proactively. The 2.83% Medicare conversion factor reduction in 2026 affects revenue directly. Diversifying into cash-pay cosmetic services helps offset that pressure without compromising care quality.
5. Set realistic patient expectations upfront. For bio-regenerative treatments and combination laser protocols, outcomes unfold over weeks to months. Patients who understand this timeline are more satisfied and less likely to discontinue mid-protocol.
6. Balance medical and cosmetic services deliberately. Learn more about structuring your practice around medical versus cosmetic services to make informed decisions about where to allocate resources.

Pro Tip: Create a one-page internal reference sheet for each new therapy or device you introduce. Include mechanism of action, ideal patient profile, contraindications, and billing codes. Staff who can answer patient questions confidently at the front desk dramatically reduce physician callback volume.

My honest take on where dermatology is headed in 2026

I’ve spent enough time thinking about how clinical fields evolve to recognize when a moment is genuinely different. And 2026 is one of those moments in dermatology.

The technology is exciting. But what I’ve found consistently is that the practices struggling most with adoption are not lacking tools. They are lacking a clear philosophy about how technology should serve the patient encounter rather than compete with it. AI can flag a suspicious lesion faster than any human. It cannot read the anxiety in a patient’s voice when they ask if it’s serious.

The convergence of precision medicine, bio-regenerative aesthetics, and AI workflow tools is real. However, the dermatologists I find most credible are those who treat new technology as an adjunct to clinical reasoning, not a replacement for it. The evidence base in medical dermatology continues to strengthen, and that should anchor every practice evolution you undertake this year.

The other thing worth saying plainly: patient expectations have shifted. They arrive better informed, more specific in what they want, and more skeptical of generic treatment plans. Meeting that expectation requires both clinical depth and communication skill. No device closes that gap for you.

— Krunal

See how Raodermatology delivers on these standards

Raodermatology has been integrating the best of medical and cosmetic dermatology for over 25 years, across locations in California, New Jersey, and New York. From skin cancer detection and treatment to the latest in cosmetic dermatology, the practice applies the same rigorous, evidence-based approach described throughout this guide. Board-certified providers use technology to support, not replace, clinical judgment. If you are looking to refer patients or explore what current best practices look like in a functioning multi-location practice, explore our services to see how the 2026 standards are already in use.

FAQ

What are the most important dermatology best practices for 2026?

The top priorities include integrating FDA-approved therapies like delgocitinib, following updated AAD pediatric guidelines, adopting AI for workflow efficiency, and expanding laser capabilities for diverse skin types. Practices that combine medical rigor with cosmetic service diversification are best positioned clinically and financially.

How does AI fit into a dermatology practice in 2026?

AI tools are most effective for triage, diagnostic support, and reducing referral wait times. They improve access in underserved populations but require paired dermatologist assessment to optimize outcomes and should not replace clinical decision-making.

What is delgocitinib and why does it matter?

Delgocitinib cream is the first FDA-approved topical treatment for adults with moderate-to-severe chronic hand eczema who have not responded to prior therapies. It works regardless of prior systemic therapy exposure, making it a significant addition to the treatment algorithm for refractory cases.

Why are combination laser protocols considered a 2026 best practice?

Layering technologies such as BBL and HALO lasers addresses multiple skin concerns simultaneously and produces results neither modality achieves alone. These stacked approaches improve patient satisfaction, support retention, and reflect where top dermatology procedures 2026 are heading.

How does the 2026 Medicare reduction affect dermatology practices?

The 2.83% Medicare conversion factor reduction directly reduces revenue for medical dermatology services. Practices that diversify into cosmetic, cash-pay procedures alongside their medical offerings are better positioned to absorb that impact without compromising care quality or staffing.

Recommended

• Medical Dermatology Essentials: Prevention, Treatment & Aesthetics | Rao Dermatology
• How to refer dermatology patients efficiently and well | Rao Dermatology
• Your dermatologist visit, step by step: a patient guide | Rao Dermatology
• Your step-by-step cosmetic dermatology consultation guide | Rao Dermatology